Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 32, Issue 11, Pages 862-874Publisher
CELL PRESS
DOI: 10.1016/j.tem.2021.08.003
Keywords
-
Categories
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health [R01DK121797, R01DK121017]
Ask authors/readers for more resources
FK506-binding protein 51 (FKBP51) is becoming recognized as a significant biomarker of metabolic dysfunction, with diverse regulatory roles in lipid metabolism, protein catabolism, and dermal adipocytes. The signaling mechanisms of FKBP51 and potential therapeutic compounds targeting it are currently being explored.
The molecular chaperone FK506-binding protein 51 (FKBP51) is gaining attention as a meaningful biomarker of metabolic dysfunction. This review examines the emerging contributions of FKBP51 in adipogenesis and lipid metabolism, myogenesis and protein catabolism, and glucocorticoid-induced skin hypoplasia and dermal adipocytes. The FKBP51 signaling mechanisms that may explain these metabolic consequences are discussed. These mechanisms are diverse, with FKBP51 independently and directly regulating phosphorylation cascades and nuclear receptors. We provide a discussion of the newly developed compounds that antagonize FKBP51, which may offer therapeutic advantages for adiposity. These observations suggest we are only beginning to uncover the complex nature of FKBP51 and its molecular chaperoning of metabolism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available